Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. Review uri icon

Overview

abstract

  • Bladder cancer is a heterogeneous disease. Non-muscle-invasive bladder cancer embraces a spectrum of tumors with varying degrees of clinical behavior. Transurethral resection remains the surgical mainstay for the treatment of non-muscle-invasive bladder cancer. In an attempt to decrease the recurrence or progression rate, intravesical chemotherapy or immunotherapy is also used. Radical cystectomy with bilateral pelvic lymph node dissection remains the gold standard for treating muscle-invasive bladder cancer. Over the last decade, the orthotopic neobladder has gained widespread popularity as the preferred mode of urinary diversion in both males and females with similar oncologic and functional outcomes. Well-designed trials with effective chemotherapy have shown a beneficial role for neoadjuvant chemotherapy.

publication date

  • December 10, 2006

Research

keywords

  • Urinary Bladder Neoplasms

Identity

Scopus Document Identifier

  • 34247346908

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.08.5431

PubMed ID

  • 17158537

Additional Document Info

volume

  • 24

issue

  • 35